SABS earnings analysis
What we found in SABS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
SAB Biotherapeutics reported no revenue for Q1 2026 while incurring a net loss of $18.87 million, significantly larger than the $5.2 million loss in Q1 2025. Operating expenses surged by 85% year-over-year, driven by increased research and development costs and general administrative expenses. The company highlighted its ongoing progress in clinical trials for its lead product candidate, SAB-142, amidst continued financial losses and reliance on future capital to support operations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Revenue Reported
- The company did not recognize any revenue for Q1 2026, the same as Q1 2025.
- Net Loss Increased
- Net loss for Q1 2026 was $18.87 million, up from $5.20 million in Q1 2025.
- Operating Expenses Rose Significantly
- Total operating expenses rose to $19.99 million in Q1 2026, compared to $10.77 million in Q1 2025, marking an 85% increase.
- R&D Expenses Surge
- Research and development expenses increased by 75% to $13.40 million in Q1 2026 from $7.66 million in Q1 2025.
- Interest Income Boosts Cash Flow
- Interest income for Q1 2026 was $1.05 million, up significantly from only $62,498 in Q1 2025.
- Strong Cash Position
- As of March 31, 2026, cash and cash equivalents totaled approximately $217.6 million, up from $143.5 million at year-end 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Reliance on Future Capital
- The company indicated it will require additional capital to fund operations going forward due to ongoing losses.
- Increased Financial Losses
- Net loss for Q1 2026 increased to $18.87 million, reflecting heightened expenses against no revenue.
- Regulatory Approval Uncertainty
- The company's future success heavily relies on the success of clinical trials and regulatory approvals for SAB-142.
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · March 9, 2026
- SAB Biotherapeutics is a clinical-stage immunoglobulin company focused on SAB-142, a fully human anti-thymocyte globulin for type 1 diabetes; the company received IND clearance in May 2024, reported positive Phase 1…
- 10-Q · August 7, 2025
- SAB Biotherapeutics reported Q2 2025 grant revenue of $0 (vs. $263,137 in Q2 2024) and a GAAP loss per share of $(1.09) (vs. $(0.79) in Q2 2024). Cash and short‑term investments fell to $3.69M and $2.02M, respectively,…
- 10-Q · May 9, 2025
- SAB Biotherapeutics reported Q1 2025 revenue of $0 (Q1 2024: $944,575) and a net loss of $5,196,773 (loss per share $0.56), driven by ongoing R&D and G&A spend. Liquidity deteriorated: cash and cash equivalents declined…
- 10-K · March 31, 2025
- SAB Biotherapeutics positions itself as a clinical-stage immunotherapy company with a proprietary Tc Bovine platform for producing human polyclonal IgG and a lead candidate, SAB-142, targeted at Type 1 Diabetes. The…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SABS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever